CATCH 2024 meeting summary: Collaborate & Address Treatment Challenges in Haemophilia

Panagiotis Christoforou; Clive Smith; Paul McLaughlin; Gary Benson; Janet Cleary; Adam Jones; Guy Maissis; Will Lester; Marie Eales; Cathy Harrison; David Stephensen; Niamh Larkin; Mark McGowan; Mark Smith; Adam Topham; Denise Player; Kate Khair

doi:10.2478/jhp-2025-0015

Abstract

Abstract

Greater treatment choice and the associated flexibility in regimens has necessitated new conversations with people with haemophilia about their personal goals. Innovations in haemophilia treatment drive the need for innovation in care service delivery. Supported by Sobi™, CATCH (Collaborate & Address Treatment Challenges in Haemophilia) is an annual, non-promotional, medical education meeting that brings together members of the haemophilia multidisciplinary team from across the UK and Ireland to discuss all aspects of haemophilia care and management. This report summarises the key issues that were explored and discussed during the CATCH 2024 meeting, including understanding the personal motivations of people with haemophilia and how these influence treatment choices and support; facilitating behaviour change to improve outcomes; reviewing the practicalities and possibilities for eliminating bleeds and new arthropathy in people with haemophilia; and developing new models of care to elevate haemophilia services.

Article

View Full Article

References

1. Lewandowska M, Nasr S, Shapiro AD. Therapeutic and technological advances in haemophilia care: Quantum leaps forward. Haemophilia 2022; 28(S4): 77–92. doi: https://doi.org/10.1111/hae.14531.
2. Coppola A, Zani M, Quintavalle G, Focosi D, Franchini M. The evolution of hemophilia pharmacological treatments and therapeutic targets at the turn of the third millennium. Semin Thromb Hemost 2025; 51(01): 010–017. doi: https://doi.org/10.1055/s-0044-1796629.
3. Valentino L, Blanchette V, Negrier C, et al. Personalising haemophilia management with shared decision making. J Haem Pract 2021; 8(1): 69–79. doi: https://doi.org/10.17225/jhp00178.
4. Berntorp E, Hermans C, Solms A, et al. Optimising prophylaxis in haemophilia A: The ups and downs of treatment. Blood Rev 2021; 50: 100852. doi: https://doi.org/10.1016/j.blre.2021.100852.
5. Hughes T, Brok-Kristensen M, Gargeya Y, et al. Treating for stability: an ethnographic study of aspirations and limitations of haemophilia treatment in Europe. J Haem Pract 2020; 7(1): 165–172. doi: https://doi.org/10.17225/jhp00169.
6. Recht M, Konkle BA, Jackson S, et al. Recognizing the need for personalization of patient-reported outcomes in the prophylaxis era. Haemophilia 2016; 22(6): 825–832. doi: https://doi.org/10.1111/hae.13066.
7. Mountains We Carry; Mountains We Climb. Dir. Rob Bradford. 2024. Available from https://youtu.be/x6xzxhybeIA?si=3Q0Ipnp-w1ZWVALS (accessed February 2025).
8. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood 2015; 125 (13): 2038–44. doi: https://doi.org/10.1182/blood-2015-01-528414.
9. Skinner M, Nugent D, Wilton P, et al. Achieving the unimaginable: Health equity in haemophilia. Haemophilia 2020; 26(1): 17–24. doi: https://doi.org/10.1111/hae.13862.
10. Rayment R, Chalmers E, Forsyth K, et al. Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B. Br J Haematol 2020; 190(5): 684–695. doi: https://doi.org/10.1111/bjh.16704.
11. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26(6): 1–158. doi: https://doi.org/10.1111/hae.14046.
12. Peyvandi F, Berger K, Seitz R, et al. Kreuth V initiative: European consensus proposal for treatment of haemophilia using standard products, extended half-life coagulant factor concentrates and non-replacement therapies. Haematologica 2020; 105(8): 2038–2043. doi: https://doi.org/10.3324/haematol.2019.242735.
13. Mannucci PM. Hemophilia therapy: the future has begun. Haematologica 2020; 105(3): 543–553. doi: https://doi.org/10.3324/haematol.2019.232132.
14. Malec L, Matino D. Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review. Haemophilia 2023; 29(6): 1419–29. doi: https://doi.org/10.1111/hae.14866.
15. Laffan M, McLaughlin P, Motwani J, et al. Expert United Kingdom consensus on the preservation of joint health in people with moderate and severe haemophilia A: A modified Delphi panel. Haemophilia 2024; 30(2): 306–319. doi: https://doi.org/10.1111/hae.14934.
16. Wilkins RA, Stephensen D, Siddle H, et al. Twelve-month prevalence of haemarthrosis and joint disease using the Haemophilia Joint Health Score: evaluation of the UK National Haemophilia Database and Haemtrack patient reported data: an observational study. BMJ Open 2022; 12(1): e052358. doi: https://doi.org/10.1136/bmjopen-2021-052358.
17. O’Hara S, Castro FA, Black J, et al. Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis. Haemophilia 2021; 27(1): 113–119. doi: https://doi.org/10.1111/hae.14171.
18. Khair K, McLaughlin P, Roussel N, et al. Prevalence and perceptions of pain in people with haemophilia: A UK study. Haemophilia 2023; 29(6): 1509–1518. doi: https://doi.org/10.1111/hae.14860.
19. Chowdary P, Khoo L, Wang M, et al. Poster PB1249 – Prospective, observational study of the clinical characteristics of adults and adolescents with severe hemophilia. International Society on Thrombosis and Haemostasis, 24–28 June, Montreal, Canada. Available from https://isth2023.eventscribe.net/fsPopup.asp?efp=VVhMVFVTWlIxNjMzNQCPresentation-ID=1255554Crn d=0.6459513Cmode=presInfo (accessed February 2025).
20. Levy-Mendelovich S, Brutman-Barazani T, Budnik I, et al. Real-world data on bleeding patterns of hemophilia A patients treated with emicizumab. J Clin Med 2021; 10(19): 4303. doi: https://doi.org/10.3390/jcm10194303.
21. Krumb E, Hermans C. Living with a “haemophilia-free mind” – The new ambition of haemophilia care? Res Pract Thromb Haemost 2021; 5(5): e12567. doi: https://doi.org/10.1002/rth2.12567.
22. Bodenheimer T, MacGregor K, Stothart N. Nurses as leaders in chronic care. BMJ 2005; 330(7492): 612–613. doi: https://doi.org/10.1136/bmj.330.7492.612.
23. Mulders G, Uitslager N, Kavanagh M, et al. The role of the specialist nurse in comprehensive care for bleeding disorders in Europe: an integrative review. Haemophilia 2024; 30(3): 598–608. doi: https://doi.org/10.1111/hae.14974.
24. Tiede A, Abdul Karim F, Jiménez-Yuste V, et al. Factor VIII activity and bleeding risk during prophylaxis for severe haemophilia A: a population pharmacokinetic model. Haematologica 2021; 106(7): 1902–1909. doi: https://doi.org/10.3324/haematol.2019.241554.
25. Chowdary P, Fischer K, Collins PW, et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia A initiated on tertiary prophylaxis. Thromb Haemost 2020; 120(5): 728–736. doi: https://doi.org/10.10155/s-0040-1709519.
26. George LA. Hemophilia A gene therapy – Some answers, more questions. N Engl J Med 2023; 388(8): 761–763. doi: https://doi.org/10.1056/NEJMe2212347.
27. Gooding R, Thachil J, Alamelu J, et al. Asymptomatic joint bleeding and joint health in hemophilia: a review of variables, methods, and biomarkers. J Blood Med 2021; 12: 209–220. doi: https://doi.org/10.2147/JBM.S304597.
28. Gochman DS. Labels, systems and motives: some perspectives for future research and programs. Health Educ Q 1982; 9(2-3): 263–70. doi: https://doi.org/10.1177/109019818200900213.
29. NICE. Behaviour change: general approaches. Public health guideline [PH6]. Published 24 October 2007. Available from https://www.nice.org.uk/guidance/ph6 (accessed February 2025).
30. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci 2011; 6: 42. doi:https://doi.org/10.1186/1748-5908-6-42.

PDF Download

Download PDF

Open in full-page viewer

Authors

Panagiotis Christoforou

Royal London Hospital, London, UK
Clive Smith

The Haemophilia Society, UK
Paul McLaughlin

Royal Free London NHS Foundation Trust, London, UK
Gary Benson

Northern Ireland Haemophilia Comprehensive Care Centre and Thrombosis Unit, Belfast, Northern Ireland
Janet Cleary

St James’s Hospital, Dublin, Ireland
Adam Jones

University of Sunderland, Sunderland, UK
Guy Maissis

Royal Free London NHS Foundation Trust, London, UK
Will Lester

University Hospitals Birmingham, Birmingham, UK
Marie Eales

Oxford University Hospitals, Oxford, UK
Cathy Harrison

Royal Hallamshire Hospital, Sheffield, UK
David Stephensen

East Kent Hospitals University NHS Foundation Trust, Canterbury, UK
Niamh Larkin

St James’s Hospital, Dublin, Ireland
Mark McGowan

St James’s Hospital, Dublin, Ireland
Mark Smith

Sobi™, UK
Adam Topham

Sobi™, UK
Denise Player

Sobi™, UK
Kate Khair

Haemnet Ltd, London, UK